Cargando…

Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies

Adult growth hormone deficiency (AGHD) is associated with an increased risk of cardiovascular (CV) disease. Long-term growth hormone (GH) treatment could improve CV outcomes. The objective of this study was to evaluate CV disease risk in patients with AGHD who received GH replacement therapy for up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höybye, Charlotte, Biller, Beverly M K, Ferran, Jean-Marc, Gordon, Murray B, Kelepouris, Nicky, Nedjatian, Navid, Olsen, Anne H, Weber, Matthias M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782424/ https://www.ncbi.nlm.nih.gov/pubmed/36347049 http://dx.doi.org/10.1530/EC-22-0267

Ejemplares similares

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER
por: Biller, Beverly M K, et al.
Publicado: (2023)

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
por: Biller, Beverly M. K., et al.
Publicado: (2021)

Sensitivity and specificity of the macimorelin test for diagnosis of AGHD
por: Garcia, Jose M, et al.
Publicado: (2020)

Sexual Dysfunction: A Neglected and Overlooked Issue in Adult GH Deficiency: The Management of AGHD Study
por: Monzani, Maria Laura, et al.
Publicado: (2021)

Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement?
por: Höybye, Charlotte, et al.
Publicado: (2014)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

THU058 Impact Of A Smartphone App On Follow-up Of Adult Growth Hormone Deficiency (AGHD) Patients: Results From The Management Of AGHD (MAGHD) Study
por: De Vincentis, Sara, et al.
Publicado: (2023)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome
por: Sjöström, Anna, et al.
Publicado: (2021)

LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS
por: Ross, Judith L, et al.
Publicado: (2022)

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet(®) IOS and Answer Program
por: Backeljauw, Philippe, et al.
Publicado: (2023)

Is GH Replacement for Adult GH Deficiency Safe?
por: Melmed, Shlomo
Publicado: (2022)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

SUN-301 Importance of Sexual Function Assessment in Multidimensional Evaluation of AGHD Patients: Results from the MAGHD Study
por: Monzani, Maria Laura, et al.
Publicado: (2020)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

GH Replacement in the Elderly: Is It Worth It?
por: Ricci Bitti, Silvia, et al.
Publicado: (2021)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020)

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
por: Brod, Meryl, et al.
Publicado: (2018)

GH deficiency in patients with spinal cord injury: efficacy/safety of GH replacement, a pilot study
por: Cuatrecasas, Guillem, et al.
Publicado: (2018)

Impact of Growth Hormone (GH) Deficiency and GH Replacement upon Thymus Function in Adult Patients
por: Morrhaye, Gabriel, et al.
Publicado: (2009)

Favorable Impacts of Growth Hormone (GH) Replacement Therapy on Atherogenic Risks in Japanese Children with GH Deficiency
por: Kohno, Hitoshi, et al.
Publicado: (2012)

Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency
por: Elbornsson, Mariam, et al.
Publicado: (2012)

Three-Year Follow-up Study on Serum Leptin Levels in GH Deficient Children with GH Replacement Therapy
por: Kishi, Megumi, et al.
Publicado: (2006)

A Case With Adult GH Deficiency Complicated With Osteogenesis Imperfecta: Effect of GH Replacement on Bone Mineral Density
por: Taguchi, Tomomi, et al.
Publicado: (2021)

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
por: Höybye, Charlotte, et al.
Publicado: (2017)

Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy - clinical implications
por: Smyczynska, Joanna, et al.
Publicado: (2010)

Macimorelin (AEZS-130)-Stimulated Growth Hormone (GH) Test: Validation of a Novel Oral Stimulation Test for the Diagnosis of Adult GH Deficiency
por: Garcia, J. M., et al.
Publicado: (2013)

Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients’ Perspective
por: Hoffman, Andrew R, et al.
Publicado: (2022)

Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency
por: Elbornsson, Mariam, et al.
Publicado: (2012)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

Early versus late initiation of GH replacement in adult-onset hypopituitarism
por: Postma, Mark R, et al.
Publicado: (2020)

Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study
por: Hou, Ling, et al.
Publicado: (2023)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023)

Correction to: “Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH”
Publicado: (2023)

Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary development and GH secretion: Frequencies, phenotypes and growth outcomes
por: Blum, Werner F., et al.
Publicado: (2018)

Effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age: Long-Term Data From NordiNet® International Outcome Study (IOS) and ANSWER Program
por: Juul, Anders, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1cvc46me85n8hsces5f2l23enh